Pietro Ravani1, Lynora Saxinger2, Uma Chandran2, Kevin Fonseca2, Stephanie Murphy2, Eddy Lang2, Laura McDougall2, Braden Manns2. 1. Departments of Medicine (Ravani, Manns) and Community Health Sciences (Ravani, Manns), and O'Brien Institute for Public Health (Ravani, Manns), and Libin Cardiovascular Institute of Alberta (Ravani, Manns), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Departments of Medicine, and Medical Microbiology and Immunology (Saxinger, Chandran), Faculty of Medicine and Dentistry, University of Alberta; Infection Prevention and Control (Chandran), Alberta Health Services, Edmonton, Alta.; Department of Microbiology, Immunology and Infectious Diseases (Fonseca), Cumming School of Medicine, University of Calgary; Alberta Precision Laboratories Calgary (Fonseca), Alberta Health Services, Calgary, Alta.; National Microbiology Laboratory (Murphy), Public Health Agency of Canada; Alberta Precision Laboratories Edmonton (Murphy), Alberta Health Services, Edmonton, Alta.; Department of Emergency Medicine (Lang), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Alberta Health Services (McDougall), Edmonton, Alta. pravani@ucalgary.ca. 2. Departments of Medicine (Ravani, Manns) and Community Health Sciences (Ravani, Manns), and O'Brien Institute for Public Health (Ravani, Manns), and Libin Cardiovascular Institute of Alberta (Ravani, Manns), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Departments of Medicine, and Medical Microbiology and Immunology (Saxinger, Chandran), Faculty of Medicine and Dentistry, University of Alberta; Infection Prevention and Control (Chandran), Alberta Health Services, Edmonton, Alta.; Department of Microbiology, Immunology and Infectious Diseases (Fonseca), Cumming School of Medicine, University of Calgary; Alberta Precision Laboratories Calgary (Fonseca), Alberta Health Services, Calgary, Alta.; National Microbiology Laboratory (Murphy), Public Health Agency of Canada; Alberta Precision Laboratories Edmonton (Murphy), Alberta Health Services, Edmonton, Alta.; Department of Emergency Medicine (Lang), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Alberta Health Services (McDougall), Edmonton, Alta.
Abstract
BACKGROUND: The prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among asymptomatic patients admitted to hospital has implications for personal protective equipment use, testing strategy and confidence in the safety of acute care services. Our aim was to estimate the positivity rate of reverse transcription polymerase chain reaction (RT-PCR) testing among people admitted to hospital without symptoms of coronavirus disease 2019 (COVID-19) in Alberta, Canada. METHODS: Between Apr. 9 and May 24, 2020, we screened for COVID-19 symptoms and tested for SARS-CoV-2 infection in all consecutive adult patients (≥ 18 yr) admitted via emergency department to 3 Alberta hospitals. We summarized the parameters of the epidemic curve and assessed the performance of symptom screening versus RT-PCR results on nasopharyngeal or oropharyngeal swab samples. RESULTS: The study period encompassed Alberta's initial epidemic curve, with peak active cases per 100 000 of 71.4 (0.07%) on Apr. 30, 2020, and 14.7 and 14.6 at the beginning (Apr. 9, 2020) and end (May 24, 2020), respectively. Testing for SARS-CoV-2 infection (64.9% throat and 35.1% nasopharyngeal swabs) was done on 3375 adults (mean age 51, standard deviation 21, yr; 51.5% men). None of the asymptomatic patients (n = 1814) tested positive, and 71 of those with symptoms tested positive (n = 1561; 4.5%, 95% confidence interval [CI] 3.6%-5.7%). Sensitivity of symptom screening (v. RT-PCR) was 100% (95% CI 95%-100%), and specificity was 55% (95% CI 53%-57%). Posttest probabilities for prevalence of SARS-CoV-2 infection ranging from 1.5 to 14 times the peak prevalence of active cases during the study did not change when we assumed lower sensitivity (92%). INTERPRETATION: In a region with low disease prevalence where protocolized symptom assessment was in place during the admission process, we did not identify people admitted to hospital without COVID-19 symptoms who were RT-PCR positive. There may not be additive benefit to universal testing of asymptomatic patients on hospital admission in a setting of low pretest probability and strong public health containment. Copyright 2020, Joule Inc. or its licensors.
BACKGROUND: The prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among asymptomatic patients admitted to hospital has implications for personal protective equipment use, testing strategy and confidence in the safety of acute care services. Our aim was to estimate the positivity rate of reverse transcription polymerase chain reaction (RT-PCR) testing among people admitted to hospital without symptoms of coronavirus disease 2019 (COVID-19) in Alberta, Canada. METHODS: Between Apr. 9 and May 24, 2020, we screened for COVID-19 symptoms and tested for SARS-CoV-2 infection in all consecutive adult patients (≥ 18 yr) admitted via emergency department to 3 Alberta hospitals. We summarized the parameters of the epidemic curve and assessed the performance of symptom screening versus RT-PCR results on nasopharyngeal or oropharyngeal swab samples. RESULTS: The study period encompassed Alberta's initial epidemic curve, with peak active cases per 100 000 of 71.4 (0.07%) on Apr. 30, 2020, and 14.7 and 14.6 at the beginning (Apr. 9, 2020) and end (May 24, 2020), respectively. Testing for SARS-CoV-2 infection (64.9% throat and 35.1% nasopharyngeal swabs) was done on 3375 adults (mean age 51, standard deviation 21, yr; 51.5% men). None of the asymptomatic patients (n = 1814) tested positive, and 71 of those with symptoms tested positive (n = 1561; 4.5%, 95% confidence interval [CI] 3.6%-5.7%). Sensitivity of symptom screening (v. RT-PCR) was 100% (95% CI 95%-100%), and specificity was 55% (95% CI 53%-57%). Posttest probabilities for prevalence of SARS-CoV-2 infection ranging from 1.5 to 14 times the peak prevalence of active cases during the study did not change when we assumed lower sensitivity (92%). INTERPRETATION: In a region with low disease prevalence where protocolized symptom assessment was in place during the admission process, we did not identify people admitted to hospital without COVID-19 symptoms who were RT-PCR positive. There may not be additive benefit to universal testing of asymptomatic patients on hospital admission in a setting of low pretest probability and strong public health containment. Copyright 2020, Joule Inc. or its licensors.
Authors: Liezl Smit; Andrew Redfern; Sadia Murray; Juanita Lishman; Marieke M van der Zalm; Gert van Zyl; Lilly M Verhagen; Corné de Vos; Helena Rabie; Annemarie Dyk; Mathilda Claassen; Jantjie Taljaard; Marina Aucamp; Angela Dramowski Journal: Afr J Emerg Med Date: 2022-04-25
Authors: Philip Davis; Rhonda Rosychuk; Jeffrey P Hau; Ivy Cheng; Andrew D McRae; Raoul Daoust; Eddy Lang; Joel Turner; Jaspreet Khangura; Patrick T Fok; Maja Stachura; Baljeet Brar; Corinne M Hohl Journal: BMJ Open Date: 2022-08-10 Impact factor: 3.006
Authors: Arjen-Kars Boer; Ruben Deneer; Maaike Maas; Heidi S M Ammerlaan; Roland H H van Balkom; Wendy A H M Thijssen; Sophie Bennenbroek; Mathie Leers; Remy J H Martens; Madelon M Buijs; Jos J Kerremans; Muriël Messchaert; Jeroen J van Suijlen; Natal A W van Riel; Volkher Scharnhorst Journal: BMJ Open Date: 2022-08-03 Impact factor: 3.006